Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
Alan's comment on GENTING. All Comments
Alan
Like · Reply
Genting's investment in TauRx Pharmaceuticals focuses on the development of hydromethylthionine mesylate (HMTM), not a vaccine. The drug recently completed Phase 3 clinical trials, showing promising results. Approval could allow public availability as early as 2025 if regulatory milestones are met. Refer sources :TauRx official website.
Report
Show more
7 months · translate ·